InxMed key facts
as of Oct 2026- Developer of cancer therapeutics designed to treat cancer.
- InxMed is valued at approximately $306.0M as of Oct 2026 (last reported valuation).
- It has raised $131.6M; the latest was IPO in Aug 2025.
- Notable investors include CMG SDIC Fund, Proxima Ventures (China), Ennovation Ventures, Shaaxi Shantou Capital, Shaanxi Growth Enterprise Guide Fund — 11 tracked in total.
- Status: In IPO Registration.
InxMed's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch InxMed: the Monday email on marks, rounds and moves
InxMed funding rounds
No funding rounds for InxMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs InxMed
11+InxMed valuation
InxMed's last reported valuation was $306 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
InxMed investors
11 investors are on record for InxMed, including CMG SDIC Fund, Proxima Ventures (China), Ennovation Ventures and Shaaxi Shantou Capital.
About InxMed
Developer of cancer therapeutics designed to treat cancer. The company currently has pharmaceuticals targeting pancreatic, ovarian, gastric and other forms of cancer, enabling healthcare professionals to prescribe more effective treatments to patients.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Employees
- 80
- Website
- inxmed.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.